Gerard Degregoris, MD
Interventional Pain Medicine · New York, NYNPI 1356589212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,913 of the $49,134 with a category attached, or 71.1%. Daiichi Sankyo Inc. accounts for 89.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $47,632 and has fallen 99.5% since, to $259 in 2025. Among interventional pain medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $534.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$44K
- Collegium Pharmaceutical, Inc.$3K
- Boston Scientific$756
- Amgen$256
- Biotronik NRO, Inc.$240
- Azurity Pharmaceuticals, Inc.$213
- plus $225 from 8 others
What the payments were for
- Consulting fees$6,66014%
- Speaking & faculty fees$34,91371%
- Travel & lodging$4,84910%
- Food & beverage$2,7126%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 44 | $43,984 |
| Collegium Pharmaceutical, Inc. | 10 | $3,460 |
| Boston Scientific | 5 | $756 |
| Amgen | 9 | $256 |
| Biotronik NRO, Inc. | 3 | $240 |
| Azurity Pharmaceuticals, Inc. | 10 | $213 |
| Medtronic | 2 | $87 |
| Pfizer | 3 | $42 |
| Novartis | 1 | $25 |
| Vertos Medical, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
| GRT US Holding, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Morphabond ER$43,317
- Xtampza ER$3,195
- WAVEWRITER ALPHA$282
- Morphabond$245
- Prospera$178
- WaveWriter Alpha Prime 16$175
- SPECTRA WAVEWRITER$136
- XTAMPZA$120
How this compares
$49,134 in reported general payments places this provider in the 90th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 11 | $389 |
| Gabapentin | 16 | $125 |
| Celecoxib | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in New York
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Marco PappagalloNew York$36K
- Jason SieffermanNew York$29K
- Barthelemy LiabaudNew York$20K
- Devi NampiaparampilNew York$18K
- Jeffrey DeygooNew York$11K
- Imran PunekarNew York$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.